Browse the evidence

Women with type 2 diabetes face a significantly higher relative risk of cardiovascular disease and mortality compared to men, despite often being diagnosed at a lower body mass index and younger age.

If you are a woman with type 2 diabetes, your risk of heart disease and death is higher relative to a man with diabetes, even if your weight is lower. This risk is amplified by hormonal changes like menopause and pregnancy history. You need aggressive management of blood pressure, lipids, and glucose, potentially starting earlier than guidelines might suggest for men, because your body may have more advanced heart vessel damage at the time of diagnosis.

Visceral adipose tissue (VAT) is a stronger independent risk factor for type 2 diabetes in women than in men, making waist circumference a more reliable predictor of risk in women.

For women, where you store fat matters more than your total weight. Visceral fat (around your organs) is a much stronger predictor of diabetes than BMI. Focus on reducing waist circumference through lifestyle changes, as this visceral fat drives insulin resistance more significantly in women than in men.

Insulin resistance (IR) is a central pathophysiological mechanism that drives the development and progression of multiple metabolic diseases, including type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver disease (NAFLD), and certain cancers.

Insulin resistance is not just a blood sugar issue; it is a systemic driver of chronic disease. Addressing it through lifestyle changes (exercise, diet) or medications (like metformin or GLP-1 agonists) can potentially improve multiple health outcomes at once, including heart health, liver health, and diabetes management. Prioritizing insulin sensitivity is a high-leverage strategy for overall metabolic health.

Obesity, particularly central/visceral obesity, is a primary cause of insulin resistance through mechanisms involving increased free fatty acids, chronic inflammation, and adipokine dysregulation.

Losing even a modest amount of weight (e.g., 10% of body weight) can significantly improve insulin sensitivity, especially if the weight is visceral fat. Focus on reducing abdominal fat through caloric deficit and exercise, as this directly addresses the root cause of obesity-induced insulin resistance.

Chronic low-grade inflammation, driven by obesity and characterized by elevated pro-inflammatory cytokines (TNF-alpha, IL-6, CRP), directly interferes with insulin signaling pathways, contributing to insulin resistance.

Chronic low-grade inflammation, common in obesity, disrupts insulin signaling. Anti-inflammatory lifestyle strategies (e.g., Mediterranean diet, regular exercise, stress management) can help reduce this inflammation and improve insulin sensitivity.

Obesity is fundamentally a state of chronic low-grade systemic inflammation driven by adipose tissue dysfunction, where an expansion of visceral fat leads to a shift from anti-inflammatory M2 macrophages to pro-inflammatory M1 macrophages, resulting in elevated levels of cytokines like TNF-alpha, IL-6, and resistin.

Recognize that obesity involves a biological inflammatory state, not just excess calories. This understanding shifts the focus from simple willpower to managing inflammation through medical and lifestyle interventions. While the paper highlights the problem, it notes that caloric restriction and regular exercise are effective interventions to reduce this inflammation and metabolic dysfunction.

Brown adipose tissue (BAT) activity is negatively associated with BMI and body fat percentage; higher BAT activity is linked to lower BMI and body fat, suggesting it plays a protective role against obesity by burning calories.

Increasing brown fat activity through exposure to cold, adequate sleep, and exercise may help counteract the decline in metabolic rate associated with higher body fat. This is a biological lever to support weight management efforts.

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) by 14% and all-cause mortality by 12% in patients with type 2 diabetes.

If you have Type 2 Diabetes and are at high risk for heart disease, ask your doctor about GLP-1 receptor agonists (like liraglutide or semaglutide). These medications have been shown to significantly reduce the risk of heart attacks, strokes, and death, in addition to helping with blood sugar control and weight loss.

Metformin reduces all-cause mortality by 36% and heart attack incidence by 39% in overweight patients with newly diagnosed type 2 diabetes without established cardiovascular disease.

If you have recently been diagnosed with Type 2 Diabetes and are overweight, metformin is likely your first medication. It not only helps control blood sugar but has been shown to significantly reduce the risk of heart attacks and death.

A 4-week multimodal prehabilitation program (high-intensity exercise, nutritional support, psychological support, and smoking cessation) significantly reduces severe and medical postoperative complications in patients undergoing elective colorectal cancer surgery.

If you are having colorectal cancer surgery, ask your care team about a prehabilitation program. It typically involves 4 weeks of supervised exercise, nutritional support, and stress management before surgery. This can significantly lower your risk of serious complications and help you recover faster.

Obesity contributes to OSAS pathogenesis by causing upper airway narrowing due to fat deposition in the pharynx and thoracic cavity, reducing vital capacity, and altering ventilation-perfusion ratios.

Losing weight can mechanically open your airway by reducing fat deposition in the neck and pharynx. This is a primary treatment strategy for OSAS, especially if you are overweight.

Elevated levels of host-accessible faecal monosaccharides (fructose, galactose, mannose, xylose) are associated with insulin resistance and metabolic syndrome in humans, mediated by gut microbiota carbohydrate metabolism.

High levels of certain sugars (fructose, galactose, mannose, xylose) found in the gut are linked to insulin resistance. This is driven by specific gut bacteria that break down complex carbs into these simple sugars. Managing gut microbiome composition through diet may help reduce these specific metabolites and improve insulin sensitivity.

Women with PCOS have an increased risk of impaired glucose tolerance and type 2 diabetes regardless of age and BMI, necessitating routine glycaemic assessment.

If you have PCOS, you need to get your blood sugar checked regularly, even if you are thin. The condition itself raises your risk for diabetes, independent of your weight. Do not skip these tests because you feel healthy or look fit.

Women with PCOS are at increased risk for cardiovascular disease and mortality, requiring lipid and blood pressure monitoring regardless of age or BMI.

You need to have your blood pressure and cholesterol checked regularly, even if you are young and feel fine. PCOS increases your risk of heart disease and stroke. This is a standard part of managing PCOS, not just for older women.

The Ketogenic Diet alters gut microbiota composition, increasing beneficial bacteria like Akkermansia and Parabacteriodes, which contributes to anti-seizure and anti-inflammatory effects.

Following a ketogenic diet changes your gut bacteria, increasing beneficial types like Akkermansia and reducing harmful ones. This shift is linked to reduced inflammation and seizure activity. You don't need to take probiotics; the diet itself drives these positive changes.

Increased energy intake, driven by the availability of cheap, energy-dense, ultra-processed foods, is the primary driver of the obesity epidemic, outweighing the contribution of reduced physical activity.

Focus on reducing caloric intake, particularly from ultra-processed, energy-dense foods, as this is the primary driver of obesity. While exercise is beneficial for health, its impact on weight management is secondary to dietary changes in the current food environment.

Critically ill patients lose approximately 2% of skeletal muscle mass per day during the first week of ICU admission, with rectus femoris thickness decreasing by 1.75% and cross-sectional area by 2.10% daily.

If you or a loved one is in the ICU, expect rapid muscle loss (approx. 2% per day) starting immediately. This is driven by inflammation, immobility, and metabolic stress. While you cannot stop the illness, early mobilization (as tolerated) and adequate protein intake are critical to slowing this specific rate of tissue breakdown.

Insulin resistance (IR) acts as a primary driver of cardiovascular disease (CVD) by promoting atherosclerosis through mechanisms including endothelial dysfunction, chronic low-grade inflammation, and dyslipidemia, independent of diabetes status.

Prioritize metabolic health markers like waist circumference and fasting insulin over just weight or cholesterol. Regular exercise and dietary modifications are the primary tools to improve insulin sensitivity and reduce cardiovascular risk, even if you are not diabetic.

Management of insulin resistance through lifestyle interventions (diet and exercise) and pharmacological agents is effective, although no medication is currently specifically approved solely for treating insulin resistance.

Focus on sustainable lifestyle changes: eat a balanced diet and exercise regularly. These are the proven ways to manage insulin resistance. Do not wait for a specific 'IR medication' as none exists; use existing tools like Metformin only if prescribed for diabetes or other conditions.

Mediterranean Diet (MD) is the recommended first-choice diet for NAFL/NASH patients, improving hepatic steatosis and visceral fat, though its efficacy in advanced NASH requires further investigation.

Adopt a Mediterranean Diet rich in whole grains and healthy fats (MUFAs). This is the recommended first-line dietary approach to reduce liver fat and visceral fat. While it helps with insulin resistance and may reduce cardiovascular risk, its ability to reverse advanced NASH is not yet fully proven.

Probiotics enhance intestinal barrier function and modulate the immune system by increasing adhesion to the intestinal mucosa, producing antibacterial substances, and reducing pro-inflammatory cytokines.

Understanding that probiotics work by strengthening your gut lining and calming inflammation helps explain why they might help with digestive issues. It is not just about 'adding good bacteria' but about how those bacteria interact with your existing gut environment to protect you.

Government-imposed pandemic containment strategies, including lockdowns and social distancing, cause a significant decline in physical activity across all age groups and genders.

Pandemic restrictions significantly reduce physical activity for most people, regardless of age or gender. To mitigate this, seek out alternative forms of exercise like digital training or home workouts, as maintaining activity is crucial for preventing negative health outcomes during lockdowns.

Insomnia disorder is an independent risk factor for the development of mental health disorders, including depression, anxiety, and suicide, suggesting that treating insomnia may have preventive value for these conditions.

Treat insomnia seriously not just for sleep quality, but as a critical step in preventing depression and anxiety. Addressing sleep problems early may reduce the risk of developing these mental health conditions.

Digital Cognitive-Behavioral Therapy for Insomnia (dCBT-I) is a cost-effective and viable method for delivering CBT-I at scale, potentially reducing healthcare expenditures.

If you cannot access a therapist for CBT-I, look for validated digital CBT-I programs. They are increasingly recognized as cost-effective and can provide the same core therapeutic benefits.